Brazil Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Brazil recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Brazil recombinant protein therapeutics cdmo market highlights
- The Brazil recombinant protein therapeutics cdmo market generated a revenue of USD 334.1 million in 2023 and is expected to reach USD 811.0 million by 2030.
- The Brazil market is expected to grow at a CAGR of 13.5% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 334.1 million |
| Market revenue in 2030 | USD 811.0 million |
| Growth rate | 13.5% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Brazil accounted for 1.6% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 811.0 million by 2030.
Interferons was the largest segment with a revenue share of 21.49% in 2023. Horizon Databook has segmented the Brazil recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The robust growth & development in biologics market is expected to boost recombinant protein therapeutics CDMO market. The growing competition for drug development and approval is anticipated to improve the demand for recombinant protein therapeutics CDMO services. In addition, membership of Brazil in the ICH has resulted in the implementation of more regulatory policies regarding the release of drug products. The growing partnership of laboratories with drug manufacturers is projected to boost the market in Brazil over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Brazil recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Brazil Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
